Fig. 5

Branch evolution demonstrates immune evasion. A Evolutionary tree illustrates tumors can exploit concurrent HLA LOH and CDKN2A/B loss to escape immune surveillance. B Co-occurrence of HLA LOH and CDKN2A/B can be seen both across regions and patients. C Differential immune response to ICI therapy in patients with CDKN2A/B loss or HLA LOH or belonging to ITH high subtype